BMS, Novartis to test combinations for NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) and Novartis AG (NYSE:NVS; SIX:NOVN) have partnered to run two Phase I/II trials to evaluate combinations of BMS' Opdivo nivolumab with three Novartis compounds to treat non-small cell lung cancer (NSCLC). The Novartis therapies are Zykadia ceritinib, INC280 and EGF816.

Opdivo is a human IgG4 mAb against programmed cell death 1 ( PDCD1; PD-1; CD279) currently under EMA review for NSCLC. BMS plans to submit a rolling BLA to FDA by year end for Opdivo as third-line treatment of squamous cell NSCLC. ...